Open access

505 IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target
X Shirley Liu, Yulong Li, Xiangyang Wu, Hailing Liu, Xi Xiao, Huizhu Liu, Qingyang Ding, Bin Xie, Caibin Sheng, Rongbin Zheng, Quan Yu, Karim A Benhadji, Xihao Hu, Tengfei Xiao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A568; DOI: 10.1136/jitc-2023-SITC2023.0505
506 CD47 antibody therapy protects circulating red blood cells and platelets from immune destruction
Maxim Markovic, Allison Banuelos, Garry Nolan, Irving Weissman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A569; DOI: 10.1136/jitc-2023-SITC2023.0506
507 Shifting the paradigm in CD47-mediated therapy; emphasizing direct agonism over ‘don’t eat me!’ inhibition
Sittana Matar, Seham Skah, Liza E Diomande, Kjetil Hestdal, Rolf Pettersen, Nina Richartz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A570; DOI: 10.1136/jitc-2023-SITC2023.0507
508 IL-15-stimulated NK cell proliferation is greatly augmented by the anti-ADAM17 mAb Medi-1 and requires CD137
Anders W Matson, Robert Hullsiek, Kate Dixon, Sam Wang, Ryan R Friess, Bruce Walcheck

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A571-A572; DOI: 10.1136/jitc-2023-SITC2023.0508
509 VISTA as a novel mechanism of tumor-associated macrophage mediated immune evasion in medulloblastoma
A Natalia, Munoz Perez, Kirsten Moziak, David M Loeb, Xingxing Zang, Allison M Martin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A573; DOI: 10.1136/jitc-2023-SITC2023.0509
510 ES008, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers
Xiaofeng Niu, Haixia Jiang, Chunnian Wang, Dawei Sun, Rui Gao, Quan Qiu, Hongtao Lu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A574; DOI: 10.1136/jitc-2023-SITC2023.0510
511 Activity of anti-CD47 antibodies is enhanced through Fc optimization
Juan C Osorio, Patrick Smith, David A Knorr, Jeffrey Ravetch

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A575-A577; DOI: 10.1136/jitc-2023-SITC2023.0511
512 Targeting HLA-E positive cancers with a novel NKG2A/C switch receptor
Michelle Saetersmoen, Ivan Kotchetkov, Lamberto Torralba-Raga, Jorge Mansilla-Soto, Silje Zandstra-Krokeide, Quirin Hammer, Michel Sadelain, Karl-Johan Malmberg

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A578; DOI: 10.1136/jitc-2023-SITC2023.0512
513 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
Kyle C Strickland, Zachary D Wallen, Sarabjot Pabla, Heidi Ko, Mary K Nesline, Rebecca A Previs, Shengle Zhang, Jeffrey M Conroy, Pratheesh Sathyan, Kamal S Saini, Taylor J Jensen, Brian Caveney, Marcia Eisenberg, Prasanth Reddy, Marc AT Muskavitch, Ken Culver, Eric A Severson, Shakti Ramkissoon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A579; DOI: 10.1136/jitc-2023-SITC2023.0513
514 Development of AIM-104, a potential best-in-class pan-allele anti-SIRPα antibody for anti-tumor therapy
Michihisa Umetani, Jessica Yu, Ariel Chen, Courtney Le, Li-Fen Lee, Kan Lu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A580; DOI: 10.1136/jitc-2023-SITC2023.0514

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages